Formulation development and manufacture of nanoparticulate - based novel antibacterials

Procarta正在使用基于纳米颗粒寡核苷酸疗法的专利技术平台开发一种治疗细菌感染的持久解决方案。该项目将使人们更好地了解如何配制和制造新型纳米抗菌剂，定义和确定关键的质量控制参数，从而形成扩大规模和进入临床试验的生产工艺。这一生产过程将成为开发一系列能够对抗现有和新出现的医院感染(MRSA和艰难梭菌超级细菌)以及新出现的革兰氏阴性感染威胁的抗菌药的坚实基础。

Procarta is developing a lasting solution to the treatment of bacterial infections using a proprietary technology platform based on nanoparticulate oligonucleotide therapeutics. This project will enable better understanding of how to formulate and manufacture novel nanoparticulate antibacterials, define and fix key QC parameters, leading to a production process for scale up and entry to clinical trials. This manufacturing process will become a strong basis for developing a range of antibacterials able to combat existing and emerging nosocomial infections (MRSA and Clostridium difficile superbugs) as well as the emerging threat of Gram negative infections.